Proliferation and significance of clinically relevant β-lactamases

Annals of the New York Academy of Sciences

Volumn 1277, Issue 1, 2013, Pages 84-90

  Bush, Karen ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Carbapenemase; ESBL; Resistance; lactam antibiotic; lactamase

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE CTX M; CARBAPENEMASE; CEPHALOSPORIN DERIVATIVE; EXTENDED SPECTRUM BETA LACTAMASE; PENICILLIN DERIVATIVE;

ARTICLE; DRUG CLASSIFICATION; DRUG NOMENCLATURE; GRAM NEGATIVE BACTERIUM; HYDROLYSIS; MULTIDRUG RESISTANCE; NONHUMAN;

EID: 84872858103     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12023     Document Type: Article

References (64)

1. Abraham, E.P. & E. Chain 1940. An enzyme from bacteria able to destroy penicillin. Nature 146: 837.
2. Abraham, E.P. 1983. History of β-lactam antibiotics. In: Antibiotics Containing the Beta-Lactam Structure Part I. A. L. Demain & N. A. Solomon, Eds.: 1-14. Springer-Verlag. Berlin
3. Fevre, C. et al. 2005. Six groups of the OXY beta-lactamase evolved over millions of years in Klebsiella oxytoca. Antimicrob. Agents Chemother. 49: 3453-3462.
4. Bhullar, K. et al. 2012. Antibiotic resistance is prevalent in an isolated cave microbiome. PLoS One 7: e34953.
5. D'Costa, V.M. et al. 2011. Antibiotic resistance is ancient. Nature 477: 457-461.
6. Bush, K. 1997. The evoution of β-lactamases. In: Antibiotic Resistance: Origins, Evolution, Selection and Spread D.J. Chadwick & J. Goode J, Eds.: 152-166. John Wiley & Sons; Chichester
7. Medeiros, A.A. 1997. Evolution and dissemination of β-lactamases accelerated by generations of beta-lactam antibiotics. Clin. Infect. Dis. 24: S19-S45.
8. Knapp, C.W. et al. 2010. Evidence of increasing antibiotic resistance gene abundances in archived soils since 1940. Environ. Sci. Technol. 44: 580-587.
9. Bush, K. & J.F. Fisher 2011. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from Gram-negative bacteria. Ann. Rev. Microbiol. 65: 455-478.
10. Thomson, K.S. 2010. Extended-spectrum-beta-lactamase, AmpC, and carbapenemase issues. J. Clin. Microbiol. 48: 1019-1025.
11. Bush, K. & G.A. Jacoby 2010. Updated functional classification of β-lactamases. Antimicrob Agents Chemother. 54: 969-976.
12. Jacoby, G.A. 2009. AmpC beta-lactamases. Clin. Microbiol. Rev. 22: 161-182.
13. Akinci, E. & H. Vahaboglu 2010. Minor extended-spectrum beta-lactamases. Exp. Rev. Antiinfect. Ther. 8: 1251-1258.
14. Canton, R. et al. 2008. IRT and CMT beta-lactamases and inhibitor resistance. Clin. Microbiol. Infect. 1: 53-62.
15. Cornaglia, G., H. Giamarellou & G.M. Rossolini 2011. Metallo-beta-lactamases: a last frontier for beta-lactams Lancet. Infect. Dis. 11: 381-393.
16. Patel, G. & R.A. Bonomo 2011. Status report on carbapenemases: challenges and prospects. Exp. Rev. Antiinfect. Ther. 9: 555-570.
17. Canton, R. et al. 2012. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin. Microbiol. Infect. 18: 413-431.
18. Tzouvelekis, L.S. et al. 2012. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Crit. Rev. Microbiol. 25: 682-707.
19. Palzkill, T. 2013. Metallo-β-lactamase structure and function. Ann. N. Y. Acad. Sci. 1277: 91-104. This volume.
20. Jacoby, G.A. & K. Bush β-lactamase classification and amino acid sequences for TEM, SHV and OXA extended-spectrum and inhibitor resistant enzymes. 2012 [updated November 1, 2012]; Available from: http://www.lahey.org/Studies/.
21. Ambler, R.P. 1980. The structure of β-lactamases. Philos. Trans. R. Soc. Lond. 289: 321-331.
22. Bush, K. 1989. Characterization of β-lactamases. Antimicrob. Agents Chemother. 33: 259-263.
23. Bush, K., G.A. Jacoby & A.A. Medeiros 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39: 1211-1233.
24. Bush, K. 2012. Antimicrobial agents targeting bacterial cell walls and cell membranes. Rev. Sci. Tech. Off. Int. Epiz. 31: 43-56.
25. Jaurin, B. & T. Grundstrom 1981. amp C cephalosporinase of Escherichia coli K-12 has a different evolutionary origin from that of β-lactamases of the penicillinase type. Proc. Natl. Acad. Sci. USA. 78: 4897-4901.
26. Huovinen, P., S. Huovinen & G.A. Jacoby 1988. Sequence of PSE-2 beta-lactamase. Antimicrob. Agents Chemother. 32: 134-136.
27. Mammeri, H. et al. 2008. Contribution of extended-spectrum AmpC (ESAC) beta-lactamases to carbapenem resistance in Escherichia coli. FEMS Microbiol. Lttr. 282: 238-240
28. Livermore, D.M. 2012. Fourteen years in resistance. Intl. J. Antimicrob. Agents. 39: 283-294.
29. Walther-Rasmussen, J. & N. Hoiby 2006. OXA-type carbapenemases. J. Antimicrob. Chemother. 57: 373-383.
30. Drawz, S.M. & R.A. Bonomo 2010. Three decades of beta-lactamase inhibitors. Clin. Microbiol. Rev. 23: 160-201.
31. Shlaes, D.M. 2013. New β-lactam-β-lactamase inhibitor combinations in clinical development. Ann. N. Y. Acad. Sci. 1277: 105-114. This volume.
32. Philippon, A., R. Labia & G. Jacoby 1989. Extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 33: 1131-1136.
33. Livermore, D.M. 2008. Defining an extended-spectrum beta-lactamase. Clin. Microbiol. Infect. 14 (Suppl1): 3-10.
34. Fong, J.J., L. Rose & E.A. Radigan 2012. Clinical outcomes with ertapenem as a first-line treatment option of infections caused by extended-spectrum beta-lactamase producing gram-negative bacteria. Ann. Pharmacother. 46: 347-352.
35. Qureshi, Z.A. et al. 2011. Risk factors and outcome of extended-spectrum beta-lactamase-producing Enterobacter cloacae bloodstream infections. Intl. J. Antimicrob. Agents. 37: 26-32.
36. Qureshi, Z.A. et al. 2012. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob. Agents Chemother 56: 2108-2113.
37. Falagas, M.E., D.E. Karageorgopoulos & P. Nordmann 2011. Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. Future Microbiol. 6: 653-666.
38. Medeiros, A.A. 1984. β-lactamases. Brit. Med. Bull. 40: 18-27.
39. Bush, K. et al. 2010. In: 50 Years of ICAAC: 1961-2010. Contributions to Science A. Delgado A, Ed. American Society for Microbiology, Washington, D.C.
40. Bradford, P.A. 2001. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14: 933-951.
41. Belaaouaj, A. et al. 1994. Nucleotide sequences of the genes coding for the TEM-like β-lactamases IRT-1 and IRT-2 (formerly called TRI-1 and TRI-2). FEMS Microbiol. Lett. 120: 75-80.
42. Brisse, S. OXY, OKP, LEN beta-lactamase protein variation home page. 2012 [October 1, 2012]; Available from: http://www.pasteur.fr/ip/easysite/pasteur/en/research/platesformes-technologiques/pasteur-genopole-ile-de-france/genotyping-of-pathogens-and-public-health-pf8/beta-lactamase-enzyme-variants/beta-lactamase-enzymevariants.
43. Frase, H. et al. 2009. Mechanistic basis for the emergence of catalytic competence against carbapenem antibiotics by the GES family of beta-lactamases. J. Biol. Chem. 284: 29509-29513.
44. Nordmann, P., G. Cuzon & T. Naas 2009. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet. Infect. Dis. 9: 228-236.
45. Barthélémy, M. et al. 1992. Close amino acid sequence relationship between the new plasmid-mediated extended-spectrum β-lactamase MEN-1 and chromosomally encoded enzymes of Klebsiella oxytoca. Biochim. Biophys. Acta. 1122: 15-22.
46. Bauernfeind, A. et al. 1996. Sequences of beta-lactamase genes encoding CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their amino acid sequences with those of other beta-lactamases. Antimicrob. Agents Chemother. 40: 509-513.
47. Matthew, M. & R.W. Hedges 1976. Analytical isoelectric focusing of R factor-determined β-lactamases: correlation with plasmid compatibility. J. Bacteriol. 125: 713-718.
48. Moland, E.S. et al. 2007. A Klebsiella pneumoniae isolate producing at least eight different beta-lactamases including an AmpC and KPC beta-lactamase. Antimicrob. Agents Chemother. 51: 800-801.
49. Dudley, M.N. 2012. Rationale for the 2010 revised susceptibility breakpoints for cephalosporins, aztreonam, and carbapenems for enterobacteriaceae. J. Ped. Infect. Dis. 1: 166-168.
50. Hombach, M., G.V. Bloemberg & E.C. Bottger 2012. Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli. J. Antimicrob. Chemother. 67: 622-632.
51. Cuzon, G. et al. 2012. Evaluation of a DNA microarray for the rapid detection of extended-spectrum β-lactamases (TEM, SHV and CTX-M), plasmid-mediated cephalosporinases (CMY-2-like, DHA, FOX, ACC-1, ACT/MIR and CMY-1-like/MOX) and carbapenemases (KPC, OXA-48, VIM, IMP and NDM). J. Antimicrob. Chemother. 67: 1865-1869.
52. Gazin, M. et al. 2012. Current trends in culture-based and molecular detection of extended-spectrum-beta-lactamase- harboring and carbapenem-resistant Enterobacteriaceae. J. Clin. Microbiol. 50: 1140-1146.
53. Nordmann, P. et al. 2012. Identification and screening of carbapenemase-producing enterobacteriaceae. Clin. Microbiol. Infect. 18: 432-438.
54. Endimiani, A. et al. 2010. Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system. J. Antimicrob. Chemother. 64: 1102-1110.
55. Savard, P. & T.M. Perl 2012. A call for action: managing the emergence of multidrug-resistant Enterobacteriaceae in the acute care settings. Curr. Opin. Infect. Dis. 25: 371-377.
56. Lascols, C. et al. 2012. Using nucleic acid microarrays to perform molecular epidemiology and detect novel beta-lactamases: a snapshot of extended-spectrum beta-lactamases throughout the world. J. Clin. Microbiol. 50: 1632-1639.
57. Chong, Y., Y. Ito & T. Kamimura 2011. Genetic evolution and clinical impact in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect. Genet. Evo. 11: 1499-1504.
58. Livermore, D.M. et al. 2008. Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06. J. Antimicrob. Chemother. 62: ii41-54.
59. Nordmann, P., T. Naas & L. Poirel 2011. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg. Infect. Dis. 17: 1791-1798.
60. Bush K. 2010. Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr. Opin. Microbiol. 13: 558-564.
61. Landman, D. et al. 2012. Transmission of carbapenem-resistant pathogens in New York City hospitals: progress and frustration. J. Antimicrob. Chemother. 67: 1427-1431.
62. Nordmann, P. et al. 2011. The emerging NDM carbapenemases. Trends Microbiol 19: 588-595.
63. Khan, A.U. & P. Nordmann 2012. Spread of carbapenemase NDM-1 producers: the situation in India and what may be proposed. Scand. J. Infect. Dis. 44: 531-535.
64. Baquero, F., T.M. Coque & F. de la Cruz 2011. Ecology and evolution as targets: the need for novel eco-evo drugs and strategies to fight antibiotic resistance. Antimicrob. Agents Chemother. 55: 3649-3660